Company Overview

Delic Holdings Corp. (OTC: DELCF; formerly listed on the Canadian Securities Exchange under DELC) is a Canada-based company that operated in the psychedelic wellness and mental health sector, with activities focused on psychedelic-assisted therapy, wellness media, and related treatment infrastructure. The company sought to build an integrated platform spanning treatment clinics, patient education, media content, and research-oriented initiatives tied to emerging psychedelic therapies. Its business model was positioned around the growing interest in mental health treatment alternatives involving ketamine-assisted therapies and regulated psychedelic medicine.

Historically, Delic expanded through acquisitions and investments in clinics, media assets, and wellness operations in North America. The company became known for combining treatment services with educational and community-building initiatives, including conferences and digital media focused on psychedelics and mental health. Public filings and market disclosures indicate that Delic experienced operational and financial challenges as capital markets for psychedelic-focused companies weakened after the sector’s rapid expansion period in 2020–2021. Certain operational details and current activity levels are difficult to verify consistently across public sources, and some data remains inconclusive based on available public disclosures.

Business Operations

Delic’s operations historically centered on several interconnected business lines, including Ketamine Wellness Centers, psychedelic wellness media, and event-based community platforms. The company generated revenue primarily through clinic-based mental health treatment services, including ketamine-assisted therapy programs administered through affiliated treatment centers in the United States. Additional activities included publishing, digital education, and conference operations tied to the psychedelic medicine ecosystem.

The company’s footprint included operations and investments in the United States and Canada, with treatment-related assets concentrated in U.S. markets. Delic also pursued partnerships with healthcare practitioners and mental health professionals involved in psychedelic-assisted treatment models. Publicly disclosed subsidiaries and operating brands included Ketamine Wellness Centers and psychedelic media-related properties associated with educational programming and industry events. Data regarding the current operational status of certain subsidiaries and assets is inconclusive based on available public sources.

Strategic Position & Investments

Delic’s strategic direction focused on becoming a vertically integrated psychedelic wellness company by combining treatment infrastructure, media engagement, and consumer education. The company pursued growth through acquisitions and strategic investments intended to expand clinic networks and establish brand recognition within the emerging psychedelic healthcare industry. Public disclosures identified acquisitions involving treatment clinic assets and media-oriented businesses during the company’s expansion phase.

The company was involved in sectors linked to psychedelic-assisted therapy, mental health treatment innovation, and wellness technology. Delic’s investment thesis aligned with broader industry expectations that regulated psychedelic therapies could become a significant component of future behavioral healthcare markets. However, changing capital market conditions, regulatory uncertainty, and industry-wide funding constraints affected the company’s growth trajectory. Available public information suggests that Delic reduced or restructured parts of its operations over time, although complete verification of all restructuring outcomes is not consistently available across independent sources.

Geographic Footprint

Delic was headquartered in Canada, while much of its operating activity and treatment infrastructure were concentrated in the United States. Its clinic-related operations historically served patients across several U.S. states through affiliated ketamine wellness centers and mental health treatment facilities. The company also maintained exposure to the broader North American psychedelic healthcare market through conferences, educational platforms, and investor-facing initiatives.

The company’s market presence was primarily focused on North America, particularly regions where ketamine-assisted treatment services operated under existing healthcare regulations. While Delic positioned itself within the global psychedelic medicine conversation, publicly verifiable operational influence outside North America appears limited. International expansion plans discussed in earlier corporate materials are not fully substantiated by later operational disclosures.

Leadership & Governance

Delic was founded during the rapid growth phase of the publicly traded psychedelic wellness industry and was led by executives with backgrounds spanning media, healthcare, wellness, and capital markets. The company’s leadership strategy emphasized integrating treatment access, public education, and brand development within the emerging psychedelic medicine ecosystem. Corporate governance and leadership structures evolved over time alongside acquisitions, restructuring activity, and changes in operating scale.

Key publicly identified executives and leadership figures have included:

• Matt Stang – Co-Founder and Former Chief Executive Officer
• Jackee Stang – Co-Founder and Former Chief Brand Officer
• Ryan Archibald – Former Chief Executive Officer
• David Harder – Former Chief Financial Officer

Publicly available information regarding the company’s current executive leadership and governance structure is limited and not consistently updated across independent sources. Data inconclusive based on available public sources.